Alzheimer%s Disease Therapeutics and Diagnostics: World Market 2013-2023 http://www.reportlinker.com/p01595396/Alzheimer%s-Disease-Therapeutics-and-Diagnostics-World-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics
Advertisement
Alzheimer's medicine - your guide to technologies, trends and revenues: Where's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead.There you find financial data, R&D trends, opportunities, and prospects. In particular, you see forecasted sales to 2023 at overall world market, submarket, product, and national level.Read on, then, to explore that industry and see what its future market could be worth.
Advertisement
Forecasts to 2023 and other analyses to help you stay ahead: Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 40 tables, 63 charts, and an interview.Many opportunities exist for diagnosis and treatment of Alzheimer's. Our study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead. Now see how you can benefit your research, analyses and decisions, also saving time.Finding data you need on that neurodegenerative disorder has just got easier. The following sections show how you benefit from our new analysis.
Discover outlooks for the world market and submarketsAlong with prediction of overall world market value to 2023, our report shows you revenue forecasting for main submarkets at world level:• Medicines for Alzheimer's disease• Diagnostics for Alzheimer's (including biomarkers).Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to develop. Assess brands too.
See forecasts for Alzheimer's drugsHow will drugs perform to 2023 at world level? Our study predicts individual revenues of three products:• Namenda• Aricept• Exelon.There you discover how high sales can go, to 2023. You see what's happening, then, understanding trends, competition, challenges, and opportunities.You find geographical revenue predictions too.
Discover prospects of national markets for those anti-dementia productsDevelopments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2013.Our analyses show you individual revenue forecasts to 2023 for nine national markets and a regional block:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• Europe (grouped forecast)• India and China.
There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.What affects producers of those diagnostic tests and medicines?Our report discusses issues and events affecting that industry and market from 2013, including these:• Research and development (R&D) - drugs, diagnostic tests, and related technologies• Disease prevalence - expanding patient populations• Disease-modifying drugs and obstacles to cures• Regulatory guidelines - changes and opportunities.
The study also discusses other aspects of diagnosing and treating Alzheimer's:• Needs for Alzheimer's treatments• Drugs and related technologies to transform the market• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging• Deep brain stimulation (functional neuromodulation)• Intellectual property (IP), licensing agreements and partnerships.That way, you explore the industry's strengths, weaknesses, opportunities, and threats. You also analyse it through Porter's five forces.See, then, what the future holds.
Prominent companies in that biomedical field and 2017 market valueOur new study predicts the world market for Alzheimer's products will reach $8.3bn in 2017, and expand fast - especially from 2018.Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2023, given the prevalence of Alzheimer's and needs for more-effective treatments.Our work thus shows you what technologies, products, and organisations hold greatest potential. In particular, the analysis investigates these companies:• Pfizer• Eisai• Forest Laboratories• Lundbeck• Novartis• TauRx Therapeutics• AC Immune.
There you assess results, product ranges, R&D pipelines, and outlooks.Prospects for Alzheimer's products and R&D are strong, and from 2013 there will arise many opportunities. Our work shows you the possibilities there, helping you stay ahead.Eight ways Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 helps youIn particular, then, our investigation gives you the following knowledge:• Revenue to 2023 for the world market - discover that industry's overall sales potential• Revenues to 2023 for world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues• Revenues to 2023 for top products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for national markets in North America, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of prominent companies - hear about developers and manufacturers' activities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities for that neurological disorder• Competition and opportunities - investigate what shapes that market's future, including ways to develop business• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.You gain information found nowhere elseThat work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.Assess progress and potential now, seeing what you can gain.
1. Executive Summary1.1 Overview of Findings1.2 Structure of the Report1.3 Research and Analysis Methods2. Alzheimer's Disease: An Introduction2.1 Neurodegenerative Diseases2.1.1 What is Alzheimer's Disease?2.1.2 What Causes Alzheimer's Disease?2.1.2.1 Alzheimer's Disease: Type 3 Diabetes?2.1.3 Management of Alzheimer's Disease2.1.4 The Socio-Economic Impact of Alzheimer's Disease2.1.5 Diagnosis of Alzheimer's Disease
3. Alzheimer's Disease Therapeutics and Diagnostics Market, 2013-20233.1 Alzheimer's Disease Therapeutics and Diagnostics Market, 20123.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2012-20173.2.1 The Market Has Been Left Exposed to Intensified Generic Competition3.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2017-20233.3.1 Healthcare Costs for Alzheimer's Disease Will Surpass All Other Medical Expenses3.3.2 The Current Drugs and Diagnostics Pipeline Is Strong3.3.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry3.4 Drivers and Restraints
4. The Alzheimer's Disease Drugs Market, 2013-20234.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer's Disease4.2 The Alzheimer's Disease Drugs Market, 20124.3 The Alzheimer's Disease Drugs Market Forecast, 2012-20174.4 The Alzheimer's Disease Drugs Market Forecast, 2017-20234.4.1 Novel Drugs Will Dramatically Alter the AD Drugs Market to 20234.4.2 A Global Aging Population Will Increase Disease Prevalence Over the Forecast Period4.5 Namenda4.5.1 Namenda Sales Forecast 2013-20234.6 Aricept4.6.1 Aricept Sales Forecast, 2013-20234.7 Exelon4.7.1 Exelon Sales Forecast, 2013-20234.8 Alzheimer's Disease Drugs Pipeline, 20134.8.1 Recent High-Profile Failures of Drugs in Development4.8.1.1 Gammagard4.8.1.2 Bapineuzumab4.8.1.3 Solanezumab4.8.1.4 Dimebon4.8.1.5 Avagacestat4.8.2 FDA to Relax Rules for the Approval of Alzheimer's Drugs4.8.3 Will Novel Drug Development Strategies Prove Successful?4.8.4 Promising Therapies in the Alzheimer's Disease Pipeline, 20134.8.4.1 Gantenerumab (Roche)4.8.4.2 TTP488 (TransTech Pharma)4.8.4.3 SB-742457 (GlaxoSmithKline)4.8.4.4 CERE-110 (Ceregene)4.8.4.5 LMTX, TRx0237 (TauRx)4.8.4.6 EVP-6124 (EnVivo Pharmaceuticals)4.8.4.7 AD02 (Affiris)4.8.4.8 Deep Brain Stimulation (Functional Neuromodulation)4.9 Leading Companies in the Alzheimer's Disease Drugs Market, 20124.9.1 Pfizer, Inc.4.9.1.1 Sales and Recent Performance Analysis, 20124.9.1.2 Pfizer: Aricept4.9.1.3 Pfizer: R&D Capabilities and Alzheimer's Disease Drug Candidates4.9.1.4 Recent Discontinued Alzheimer's Disease Projects4.9.2 Eisai Co., Ltd4.9.2.1 Sales and Recent Performance Analysis, 20124.9.2.2 Eisai: Aricept4.9.2.3 Alzheimer's Disease Drug Pipeline4.9.2.4 Partnership with GE Healthcare for Diagnostic Development4.9.3 Forest Laboratories4.9.3.1 Sales and Recent Performance Analysis, 20124.9.3.2 Forest: Namenda4.9.4 Lundbeck A/S4.9.4.1 Sales and Recent Performance Analysis, 20124.9.4.2 Ebixa4.9.4.3 Alzheimer's Disease Drug Pipeline4.9.5 Novartis AG4.9.5.1 Sales and Recent Performance Analysis, 20124.9.5.2 Novartis: Exelon4.9.5.3 eHealth Programme: Delivering Innovation4.9.5.4 Alzheimer's Disease Drug Pipeline4.9.6 TauRx4.9.6.1 Partnership with Bayer Schering Pharma AG4.9.7 AC Immune4.9.7.1 Groundbreaking $100m Trial for Alzheimer's Therapy4.9.7.2 AC Immune Halts Development of AC-91
5. The Alzheimer's Disease Diagnostics Market, 2013-20235.1 There is Still a Strong Market Need for Effective Diagnosis5.2 The Alzheimer's Disease Diagnostics Market, 20125.3 New Criteria and Guidelines to Diagnose Alzheimer's Disease5.4 Biomarkers for Alzheimer's Disease5.4.1 Leading Companies Pursuing Novel Biomarker Development Strategies5.5 Alzheimer's Disease: Advances in Diagnostic Imaging Technologies5.5.1 Structural Imaging5.5.2 Functional Imaging5.5.3 Molecular Imaging Technologies5.5.3.1 Pittsburgh Compound B (PIB)5.5.3.2 18F Flutemetamol5.5.3.3 Florbetapir F18 (18F-AV-45)5.5.3.4 Florbetaben (Bay 94-9172)5.5.3.5 Other Alzheimer's Radiotracers in Development5.6 Alzheimer's Disease Diagnostics Market Forecast, 2012-20175.7 Alzheimer's Disease Diagnostics Market Forecast, 2017-20225.8 Leading Companies in The Alzheimer's Disease Diagnostics Market, 20135.8.1 Eli Lilly5.8.1.1Recent Performance and Sales Analysis, 20125.8.1.2 Alzheimer's Disease Research Efforts5.8.1.2.1 Solanezumab5.8.1.2.2 Amyvid5.8.1.2.3 Amyvid Receives Marketing Authorization from the European Commission5.8.1.2.4 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme5.8.2 DiaGenic5.8.2.1 Collaborative Agreement with Pfizer5.8.3 Amarantus BioScience Holdings, Inc.5.8.3.1 LymPro5.8.3.2 Intellectual Property Acquisitions5.8.4 Piramal Enterprises5.8.4.1 Piramal Imaging SA5.8.4.2 Regulatory Acceptance for Review of Florbetaben5.8.4.3 Manufacturing and Distribution Agreements5.8.5 GE Healthcare5.8.5.1 GE's Commitment to Imaging Research in the Alzheimer's Field5.8.5.2 Regulatory Acceptance for Review of Flutemetamol5.8.5.3 Licensing Agreements for Flutemetamol
6. The Leading National Markets, 2013-20236.1 Regional Breakdown of the Global Alzheimer's Disease Therapeutics and Diagnostics Market, 20126.1.1 The US and Europe Represent More Than 70% of the Total Market6.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Forecast, 2013-20236.3 Changing Market Shares of Leading National Markets, 2013-20236.4 The US Alzheimer's Disease Therapeutics and Diagnostics Market, 2012-20236.4.1 One in Eight Over the Age of 65 has AD in the US6.4.2 The US Will Remain the Largest Market Over the Forecast Period6.5 The European Alzheimer's Disease Therapeutics and Diagnostics Market, 2012-20236.5.1 Germany 2012-2023: The Largest European Market6.5.2 The French Market, 2012-2023: Highest Healthcare Spender in Europe6.5.3 The UK Market, 2012-2023: Spending Restrictions6.5.4 The Spanish Market, 2012-2023: Cost Containment Measures Will Continue to Affect the Market6.5.5 The Italian Market, 2012-20236.6 The Japanese Market, 2012-2023: The Second Largest National Market in 20126.7 The Chinese Market, 2012-2023: One of the Fastest Growing Markets6.8 The Indian Market, 2012-2023: Improvements in Regulations Will Boost the Market to 2023
7. Qualitative Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 20137.1 SWOT Analysis7.2 Strengths7.2.1 Alzheimer's Disease is a High Profile Disease7.2.2 Expanding Patient Population7.2.3 Strong R&D Pipeline in Both Sectors of the Market7.3 Weaknesses7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer's Disease7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market7.4 Opportunities7.4.1 Regulators Seeking Improved Standards of Alzheimer's Disease Drug Development7.4.2 Neurodegenerative Diseases Have Strong R&D7.4.3 Emerging Markets Will Help Drive the Market7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration7.5 Threats7.5.1 Patent Expiries Will Lead to Further Generic Competition7.5.2 New AD Therapies Face Political, Commercial and Social Pressures7.6 Porter's Five Force Analysis7.6.1 Rivalry Among Competitors7.6.2 Threat of New Entrants7.6.3 Power of Suppliers7.6.4 Bargaining Power of Suppliers7.6.5 Threat of Substitutes
8. Research Interview8.1 Interview with Professor Jürgen Götz8.1.1 The Obstacles for Developing a Cure for Alzheimer's Disease8.1.2 The Time Frame for Developing a Cure for Alzheimer's Disease8.1.3 Potential Alzheimer's Disease Treatments8.1.4 The Market Potential for a Cure for Alzheimer's Disease9. Conclusions9.1 Disease-Modifying Drugs and Novel Diagnostic Technologies Will Transform the Market9.2 Demographics Will Help Drive the Market Over the Forecast Period9.3 Medicines and Diagnostic Tests for Alzheimer's Disease Hold Great Potential from 2013 to 2023
List of TablesTable 2.1 Leading Sectors in the Neurodegenerative Disease Market, 2013Table 2.2 Imaging Technologies Used in Alzheimer's Research, 2013Table 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2012Table 3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2012-2017Table 3.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2017-2023Table 3.4 The Alzheimer's Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2013Table 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012Table 4.2 Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2017Table 4.3 Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2017-2023Table 4.4 Selected List of Alzheimer's Disease Drugs in the Pipeline, 2013Table 4.5 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2012Table 4.6 Pfizer: Aricept Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023Table 4.7 Pfizer: Alzheimer's Disease Drug Pipeline, 2013Table 4.8 Eisai: Aricept Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023Table 4.9 Forest: Namenda's Historical Revenues ($bn), AGR (%) and Percentage of Net Sales (%), 2009-2013Table 4.10 Forest: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2012-2023Table 4.11 Lundbeck: Revenues ($bn) and Revenue Shares (%) by Region, 2012Table 4.12 Ebixa: Revenues ($bn) and Revenue Shares (%) by Region, 2012Table 4.13 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2012-2023Table 4.14 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2012Table 5.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2012Table 5.2 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Sector, 2012-2017Table 5.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Sector, 2017-2023Table 5.4 Diagenic: Diagnostics Pipeline, 2013Table 6.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Region, 2012Table 6.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Region, 2012-2017Table 6.3 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Region, 2017-2023Table 6.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2017, 2017-2023 and 2012-2023Table 6.5 Market Shares (%) of the Leading Regional Alzheimer's Disease Therapeutics and Diagnostics Markets, 2012, 2017 and 2023Table 6.6 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023Table 6.7 The European Alzheimer's Therapeutics and Diagnostics Market: Revenues ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2012Table 6.8 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Leading Country, 2012-2017Table 6.9 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Leading Country, 2017-2023Table 6.10 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023Table 6.11 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023Table 6.12 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023Table 6.13 India: Population Forecast by Age Group (%), 2010, 2015 and 2020Table 7.1 SWOT Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2013Table 9.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, in 2012, 2017 and 2023Table 9.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2012, 2017 and 2023
List of FiguresFigure 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Sector, 2012Figure 3.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Sector, 2012Figure 3.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2017Figure 3.4 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2017-2023Figure 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2012Figure 4.2 The Alzheimer's Disease Drugs Market: Market Shares (%) by Leading Drugs, 2012Figure 4.3 The Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), 2012-2017Figure 4.4 The Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), 2017-2023Figure 4.5 The Other Treatments Market Forecast: Revenues ($bn), 2012-2023Figure 4.6 Namenda: Revenue Forecast ($bn), 2012-2023Figure 4.7 Aricept: Sales Forecast ($bn), 2012-2023Figure 4.8 Exelon: Sales Forecast ($bn), 2012-2023Figure 4.9 Pfizer: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2009-2012Figure 4.10 Pfizer: Revenues ($bn) by Sector, 2012Figure 4.11 Pfizer: Revenue Shares (%) by Sector, 2012Figure 4.12 Pfizer: Aricept Historical Revenues ($bn) and Annual Growth Rates (%), 2008-2012Figure 4.13 Pfizer: Aricept Revenue Forecast ($bn), 2012-2023Figure 4.14 Pfizer: Historical R&D Expenditure ($bn) and R&D Expenditure as Percentage of Revenue (%), 2009-2012Figure 4.15 Eisai: Aricept Revenue Forecast ($bn), 2012-2023Figure 4.16 Forest Laboratories: Historical Revenues ($bn), Net Income/Loss ($bn) and Profit Margin (%), 2009-2013Figure 4.17 Forest: Namenda's Historical Revenues ($bn) and AGRs (%), 2009-2013Figure 4.18 Forest: Namenda's Quarterly Revenues ($bn), Fiscal Year 2013Figure 4.19 Forest: Namenda Sales Forecast ($bn), 2012-2023Figure 4.20 Lundbeck: Revenue Shares (%) by Region, 2012Figure 4.21 Lundbeck: Revenues ($bn) by Region, 2012Figure 4.22 Ebixa: Revenue Shares (%) by Region, 2012Figure 4.23 Ebixa: Sales Forecast ($bn), 2012-2023Figure 4.24 Novartis: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2009-2012Figure 4.25 Novartis: Revenues ($bn) by Segment, 2012Figure 4.26 Novartis: Revenue Shares (%) by Segment, 2012Figure 4.27 Exelon: Revenue Shares (%) by Region, 2012Figure 5.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) by Segment, 2012Figure 5.2 The Alzheimer's Disease Diagnostics Market: Market Shares (%) by Segment, 2012Figure 5.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2012-2017Figure 5.4 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2017-2023Figure 5.5 Eli Lilly: Historical Revenues ($bn), Net Income ($bn), Profit Margin (%), 2010-2012Figure 6.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2012Figure 6.2 The Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2012Figure 6.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2017Figure 6.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2017-2023Figure 6.5 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2023Figure 6.6 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (% by Region, 2017Figure 6.7 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2023Figure 6.8 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast ($bn), 2012-2023Figure 6.9 US Demographics: No. of People Aged 65 or Over, 2012 and 2022Figure 6.10 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Leading Countries, 2012Figure 6.11 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Leading Countries, 2012Figure 6.12 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast ($bn), 2012-2023
Figure 6.13 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%) by Leading Countries, 2012-2023Figure 6.14 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.15 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.16 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.17 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.18 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.19 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.20 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023Figure 6.21 China's Historical Healthcare Expenditure ($bn), 2001-2010Figure 6.22 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn), 2012-2023Figure 7.1 Proportion of Population (%) Aged 60 or Over: World, 1950, 2009 and 2050Figure 7.2 Porter's Five Force Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2013Figure 9.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2012, 2017 and 2023Figure 9.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Leading Countries in 2012, 2017 and 2023Figure 9.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Segment in 2012, 2017 and 2023
Companies ListedAbbott LaboratoriesAC ImmuneAdamas PharmaceuticalsAffirisAlzheimer's AssociationAmarantus Bioscience Holdings American Academy of NeurologyAstraZenecaAvid RadiopharmaceuticalsBaxter InternationalBayerBioArctic NeuroscienceBristol-Myers SquibbCeregeneCytosDiaGenicEisaiElanEli LillyEnVivo PharmaceuticalsEuropean Medicines Agency (EMA)Forest LaboratoriesFood and Drug Administration (US FDA)French Economic CommitteeFunctional NeuromodulationGE HealthcareGlaxoSmithKline (GSK)Healthcare Ministry (China)IBA MolecularJanssen PharmaceuticalsJohnson and Johnson (J&J)LundbeckMedivationMemoryDxMerck & Co.MerzMount Sinai School of MedicineNanotherapeuticsNational Institute of AgingNovartisOtsuka PharmaceuticalPfizerPiramal EnterprisesPiramal ImagingPower3 Medical ProductsProterraQR PharmaRaptor PharmaceuticalsRocheSanko JunyakuSanofiShireSiemens Medical SolutionsSonexa TherapeuticsTauRx PharmaceuticalsToyama Chemical Co.Transition TherapeuticsTransTech PharmaUnited Nations (UN)University of California, Los Angeles (UCLA)Wyeth (now part of Pfizer)
To order this report:Diagnostics Industry: Alzheimer%s Disease Therapeutics and Diagnostics: World Market 2013-2023
Contact Clare: [email protected] US:(339) 368 6001 Intl:+1 339 368 6001
SOURCE Reportlinker
